Yakov Datsenko

836 citations
13 papers · 686 · 1 hit paper · h-index 10

Impact in

  • Hepatology top 5%
    • Hepatitis C virus research
    • Spondyloarthritis Studies and Treatments
    • Rheumatoid Arthritis Research and Therapies

Papers in

Yakov Datsenko

13 papers receiving 674 citations

Yakov Datsenko's Hit Papers

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study 2018 · 318 citations
3180+2+5Years since publication100200300

Peers

Yakov Datsenko
Comparison fields: 5 of 24
  • Hepatology 270
  • Rheumatology 261
  • Immunology 121
  • Pharmacology 26
  • Dermatology 13
Replace Feyza Gündüz with:
Feyza Gündüz Türkiye
Hubert J. F. van Hoogstraten Netherlands
Leila Maria Moreira Beltrão Pereira Brazil
Richard Hagan Ireland
Florence Villard‐Truc France
Stéphane Gayet France
Jannie W. den Ouden Netherlands
D. Ponard France
Valentina Strohmeier Germany
Kate Diana Lynch Australia
Yakov Datsenko relative to Feyza Gündüz Türkiye Feyza Gündüz's profile →
Citations per field
00.5×5×12.4×
Feyza Gündüz · 1×
Citations per year

Countries citing papers authored by Yakov Datsenko

Since Specialization
Citations

This map shows the geographic impact of Yakov Datsenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yakov Datsenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yakov Datsenko more than expected).

Fields of papers citing papers by Yakov Datsenko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yakov Datsenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yakov Datsenko. The network helps show where Yakov Datsenko may publish in the future.

Co-authors

The 25 scholars most cited alongside Yakov Datsenko, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yakov Datsenko Line = papers co-authored together Yakov Datsenko links everyone, so they are left out of the graph.

All Works

13 of 13 papers shown
#Work
1
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
Hit paper breakdown →
2018318
2 201391
3 202177
4 201363
5 201330
6 201129
7 201125
8 201517
9 201015
10 201412
11 20124
12 20134
13 20231

About Yakov Datsenko

Yakov Datsenko is a scholar working on Hepatology, Rheumatology, Immunology, Public Health, Environmental and Occupational Health and Nuclear Energy and Engineering, having authored 13 papers that have together received 686 indexed citations. Recurring topics across this work include Hepatitis C virus research (10 papers), Ethics in Clinical Research (1 paper), Psoriasis: Treatment and Pathogenesis (1 paper) and Spondyloarthritis Studies and Treatments (1 paper). The work is most often cited by research in Hepatology (270 citations), Rheumatology (261 citations), Immunology (121 citations), Pharmacology (26 citations) and Dermatology (13 citations). Yakov Datsenko has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Steven J. Padula, Stella Aslanyan, Alan M. Solinger, Joachim Sieper, Chandrasena R. Pamulapati, Carlo Salvarani, Lai‐Shan Tam, Paul R. Scholl, James Cheng‐Chung Wei and Sudha Visvanathan. Their work appears in journals such as Journal of Hepatology, Antimicrobial Agents and Chemotherapy, Hepatology, Dermatology and Therapy and The American Journal of Gastroenterology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact